Whitehawk Therapeutics Inc Dossier - Source-backed chat

Whitehawk Therapeutics Inc

WHWKNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)0.86

Intrinsic Value $3.37median of 2 methodsbased on filings through 30 Jun 2026

Market Price $3.76Price as of 30 Sep 2026

Near fair valueIntrinsic value is 10% below the market price

−50% · IV below pricenear fair value ±15%IV above price · +50%

Data confidence Sign in to view data confidence

Market Cap $214.4M

Enterprise Value $129.1M

Shares Outstanding 57M diluted

Next Earnings Date5 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Whitehawk Therapeutics, Inc. (formerly Aadi Bioscience, Inc.) represents a compelling, high-potential investment opportunity in the rapidly expanding antibody-drug conjugate (ADC) oncology space. Following its strategic transformation in early 2025—which included the divestiture of its legacy commercial FYARRO business to Kaken Pharmaceuticals for $100 million—Whitehawk has pivoted entirely to a next-generation, three-asset ADC portfolio. Backed by a robust balance sheet bolstered by a recent $87.5 million PIPE financing in May 2026, the company's cash runway is extended into the second half of 2028. This provides a substantial buffer to reach critical clinical inflection points, specifically the initial Phase 1 data readouts for its lead assets, HWK-007 and HWK-016, expected in the first half of 2027. By leveraging established tumor biology targets (PTK7, MUC16, and SEZ6) and pairing them with Hangzhou DAC's advanced CPT113 linker-payload and its proprietary Carbon Bridge Cysteine Re-pairing (CBCR) platform, Whitehawk is well-positioned to deliver therapies with superior therapeutic indices and safety profiles compared to first-generation predecessors.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets6 analysts · as of 18 Aug 2026

Low · most bearish analyst$4.00

Mean target$7.50

High · most bullish analyst$10.00

Street targets sit above today's price; our intrinsic value sits below it. Different horizons, different questions.

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 19 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$3.0020%

In the bear case, Whitehawk encounters unexpected dose-limiting toxicities (DLTs) in its Phase 1 trials for HWK-007 or HWK-016, severely limiting the therapeutic index and delaying development timelines. Additionally, the IND submission for HWK-206 faces regulatory delays, pushing the clinical entry into 2027. High clinical development costs accelerate the cash burn rate, shortening the runway and forcing the company to raise capital through highly dilutive equity offerings at depressed valuations, significantly impacting shareholder value.

Base CaseCentral scenario

$6.5050%

The base case assumes steady clinical execution across the three-asset ADC portfolio. Phase 1 dose-escalation trials for HWK-007 and HWK-016 proceed without major safety hurdles, establishing a recommended Phase 2 dose (RP2D) and showing encouraging preliminary anti-tumor activity by 1H 2027. The IND for HWK-206 is submitted in mid-2026, and the Phase 1 trial initiates in Q3 2026 as planned. Disciplined cost management keeps quarterly cash burn manageable, preserving the cash runway into 2H 2028. The stock trades up toward the consensus analyst target as clinical milestones are systematically achieved.

Bull CaseUpside scenario

$8.0030%

In the bull case, Whitehawk's proprietary CBCR platform demonstrates exceptional clinical safety and early efficacy signals in its ongoing Phase 1 trials for HWK-007 (targeting PTK7) and HWK-016 (targeting MUC16) by 1H 2027. HWK-206 successfully enters the clinic in Q3 2026 and shows rapid, deep tumor regressions in small-cell lung cancer (SCLC) models, validating its unique biparatopic design. The strong clinical data triggers a lucrative global co-development partnership with a major pharmaceutical company, bringing in a massive upfront cash payment and validating the platform. This non-dilutive funding, combined with existing cash, extends the runway beyond 2030 and drives the stock price toward the high-end analyst target.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Fully funded clinical development program with a cash runway extending into the second half of 2028, following the $100M FYARRO divestiture and the $87.5M PIPE financing in May 2026.
Differentiated next-generation ADC architecture utilizing Hangzhou DAC's CPT113 linker-payload and proprietary CBCR bioconjugation, designed to improve plasma stability and therapeutic index.
Targeting clinically validated but underexploited tumor targets (PTK7, MUC16, SEZ6) with high unmet medical needs in lung, ovarian, and neuroendocrine cancers.
HWK-206 is the only biparatopic ADC in development for small-cell lung cancer (SCLC), offering a unique competitive advantage.
Experienced leadership team with deep expertise in oncology drug development and successful execution, led by CEO Dr. David Lennon and CMO Dr. Margaret Dugan.

Key Investment Risks

Early-stage clinical risk: Lead programs (HWK-007 and HWK-016) are in Phase 1 dose-escalation, and there is currently no published human safety or efficacy data.
Regulatory and timeline risk: The IND submission for HWK-206 is planned for mid-2026, and any regulatory feedback or clinical hold could delay the Q3 2026 Phase 1 trial initiation.
High reliance on third-party technology: The ADC assets are in-licensed from WuXi Biologics and Hangzhou DAC, exposing the company to partner execution and supply chain risks.
Intense competition: The ADC landscape is highly crowded, with major pharmaceutical companies and well-funded biotechs aggressively developing competing platforms.

Thesis Invalidation Triggers

Occurrence of severe, off-target dose-limiting toxicities (such as severe neutropenia or interstitial lung disease) in Phase 1 trials that halt development of HWK-007 or HWK-016.
Failure of HWK-007 or HWK-016 to demonstrate meaningful preliminary anti-tumor activity (e.g., low objective response rates) in their respective target populations during Phase 1 expansion.
Significant delay (greater than 6 months) in the IND filing or Phase 1 initiation of HWK-206.
Rapid acceleration of cash burn that reduces the projected cash runway to less than 12 months without a clear path to non-dilutive funding.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.